BARD1 Appoints world-leading medical researcher as CSO
- BARD1 Life Sciences (BD1) appoints Greg Rice as chief scientific officer (CSO) to fast-track development of its cancer diagnostic tests
- Dr Rice has more than 30 years experience across oncology, perinatology, exosome-based research and clinical translational research
- He will lead BD1’s R&D programs with a focus on advancing its tests for breast and ovarian cancers towards clinical and commercial milestones
- Former CSO Peter French will transition to a new position as the company’s strategic technology advisor
- Shares are down 0.38 per cent at $1.31 at 12:52 pm AEST
